Who owns the ONCONIC THERAPEUTICS trademark?

The ONCONIC THERAPEUTICS trademark is owned by Onconic Therapeutics Inc..

What is the serial number for ONCONIC THERAPEUTICS?

The USPTO serial number for ONCONIC THERAPEUTICS is 79384047.

What is the registration number for ONCONIC THERAPEUTICS?

ONCONIC THERAPEUTICS is registered under USPTO registration number 7592630.

ONC

USPTO Trademark Record

REGISTERED

ONCONIC THERAPEUTICS

Q: What class is the ONCONIC THERAPEUTICS trademark registered in?

The ONCONIC THERAPEUTICS trademark is registered in Class 005 (Pharmaceuticals, medical & veterinary preparations), Class 035 (Advertising, business management & retail services).

SN 79384047·Reg 7592630·Filed Oct 17, 2023

Owner Onconic Therapeutics Inc.

Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary purposes, food for babies; dietary supplements for human beings and animals; adhesive plasters, materials for dressings; material for filling teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.; Advertising; business management, organization and administration; office functions.

ONCONIC THERAPEUTICS (Serial No. 79384047), Registration No. 7592630, is a registered US trademark filed on Oct 17, 2023 by Onconic Therapeutics Inc.. This trademark covers Class 005 (Pharmaceuticals, medical & veterinary preparations), Class 035 (Advertising, business management & retail services).

early section 8: December 10, 2030

Mark Intelligence

ONCONIC THERAPEUTICS (Reg. #7592630) is a registered US trademark that has been protecting its owner, Onconic Therapeutics Inc., since 2023. The mark covers Class 005 (Pharmaceuticals, medical & veterinary preparations) and Class 035 (Advertising, business management & retail services) respectively. Goods and services include Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and subs.... The mark faced 4 opposition proceedings during prosecution.

FILED

Oct 17, 2023

SERIAL

79384047

REG#

7592630

REGISTERED

Dec 10, 2024

Owner

Applicant

Onconic Therapeutics Inc.

Entity

Corporation

Address

11F, 12 Teheranro-26-gil, Gangnam-gu, Seoul 06236

Country

Attorney

NameJohn M. Kim

Law firm

John M. Kim IPLA, LLP

Address

4445 Eastgate Mall, Suite 200, San Diego, CA 92121, United States

Get pre-filing clearance

AI attorney analyzes your proposed mark against USPTO — Go/No-Go verdict, class-by-class risks, and strategy recommendations.

Run clearance

Filing Information

StatusREGISTERED

Filing DateOct 17, 2023

Serial Number79384047

Registration No.7592630

Registration DateDec 10, 2024

Status DateDec 10, 2024

Published for OppositionOct 08, 2024

Mark TypeStandard characters

Status DescriptionLive and registered

Filing Signals

FILED

2023

YEARS AGO

CLASSES

MADRID FILINGS

—

Opposed 4× during prosecution

Search 14M+ trademarks

Free USPTO lookups by name, owner, or serial number. No account needed.

Search now

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 005Pharmaceuticals, medical & veterinary preparations

US codes: 005, 006, 018, 044, 046, 051, 052

Class 035Advertising, business management & retail services

US codes: 100, 101, 102

Advertising; business management, organization and administration; office functions.

This description is as filed with the USPTO and defines the scope of trademark protection.

Status History

25 events

FINAL DECISION TRANSACTION PROCESSED BY IB

Jun 06, 2025

FINAL DECISION TRANSACTION PROCESSED BY IB

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

May 17, 2025

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

FINAL DISPOSITION NOTICE SENT TO IB

May 16, 2025

FINAL DISPOSITION NOTICE SENT TO IB

FINAL DISPOSITION PROCESSED

May 15, 2025

FINAL DISPOSITION PROCESSED

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

Apr 29, 2025

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

Apr 29, 2025

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Mar 10, 2025

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

REGISTERED-PRINCIPAL REGISTER

Dec 10, 2024

REGISTERED-PRINCIPAL REGISTER

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Dec 10, 2024

NOTICE OF REGISTRATION CONFIRMATION EMAILED

PUBLISHED FOR OPPOSITION

Oct 08, 2024

PUBLISHED FOR OPPOSITION

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Oct 08, 2024

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Sep 18, 2024

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

APPROVED FOR PUB - PRINCIPAL REGISTER

Sep 04, 2024

APPROVED FOR PUB - PRINCIPAL REGISTER

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Jul 31, 2024

TEAS RESPONSE TO OFFICE ACTION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jul 31, 2024

CORRESPONDENCE RECEIVED IN LAW OFFICE

TEAS/EMAIL CORRESPONDENCE ENTERED

Jul 31, 2024

TEAS/EMAIL CORRESPONDENCE ENTERED

REFUSAL PROCESSED BY IB

Jul 20, 2024

REFUSAL PROCESSED BY IB

REFUSAL PROCESSED BY MPU

Jun 29, 2024

REFUSAL PROCESSED BY MPU

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

Jun 29, 2024

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Jun 15, 2024

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

NON-FINAL ACTION WRITTEN

Jun 07, 2024

NON-FINAL ACTION WRITTEN

ASSIGNED TO EXAMINER

Jun 03, 2024

ASSIGNED TO EXAMINER

APPLICATION FILING RECEIPT MAILED

Dec 08, 2023

APPLICATION FILING RECEIPT MAILED

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Dec 04, 2023

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

SN ASSIGNED FOR SECT 66A APPL FROM IB

Nov 30, 2023

SN ASSIGNED FOR SECT 66A APPL FROM IB

ONCONIC THERAPEUTICS

Get pre-filing clearance

Search 14M+ trademarks

Run a conflict check

Other Marks by Onconic Therapeutics Inc.

Other Marks in Class 005 — Pharmaceuticals, medical & veterinary preparations

Other Marks by John M. Kim

Resources

Company